CD44+/CD24-/low及ALDH1+与早期乳腺癌预后相关性比较  

Comparison of correlation between CD44+/CD24-/low and ALDH1+ with prognosis of early stage breast cancer

作　　者：李芳华 张晓[2] LI Fanghua;ZHANG Xiao(Department of pathology,Sichuan Provincial People′s Hospital,University of Electronic Science and Technology of China,Chengdu 611731,China;Department of breast surgery,Sichuan Provincial Peo⁃ple′s Hospital,University of Electronic Science and Technology of China,Chengdu 611731,China)

机构地区：[1]四川省医学科学院·四川省人民医院病理科,成都611731 [2]四川省医学科学院·四川省人民医院乳腺外科,成都611731

出　　处：《岭南现代临床外科》2019年第6期662-667,672,共7页Lingnan Modern Clinics in Surgery

基　　金：四川省卫生健康委普及应用项目(16PJ477)

摘　　要：目的比较CD44^+/CD24^-/low及ALDH1+与早期乳腺癌预后的相关性。方法回顾性选取我科2007年4月至2008年2月因早期乳腺癌行手术患者510例,收集其术后石蜡包埋肿瘤标本,用免疫组化检测其CD44、CD24及ALDH1的表达情况,比较CD44^+/CD24^-/low组及ALDH1+组同总生存的相关性。结果 CD44^+/CD24^-/low的比例为22.9%,ALDH1+的比例为11.1%。在多因素Cox比例风险模型控制混杂变量后,CD44^+/CD24^-/low组总生存同非CD44^+/CD24^-/low组无显著性差异(HR=1.335,95%CI:0.812-2.193,P=0.254);ALDH1+组总生存低于ALDH1-组(HR=1.736,95%CI:0.385-0.864,P=0.008)。结论 ALDH1+可作为早期乳腺癌预后不良的标志物,而CD44^+/CD24^-/low表型不能作为早期乳腺癌预后不良的标志物。Objective to compare the correlation between CD44^+/CD24^-/low and ALDH1+with overall survival of early stage breast cancer.Methods 510 cases of patients undergoing surgery for early stage breast cancer from April 2007 to February 2008 in our department were retrospectively selected.Paraffinembedded tumor specimens were collected after surgery,and the expressions of CD44,CD24 and ALDH1 were detected by immunohistochemistry,and the correlation between CD44^+/CD24^-/low group and ALDH1+group with overall survival was compared.Results The proportion of CD44^+/CD24^-/low was 22.9%,and the proportion of ALDH1+was 11.1%.After controlling for confounding variables in the multivariate Cox proportional risk model,there was no significant difference in the overall survival between the CD44^+/CD24^-/low group and the non-CD44^+/CD24^-/low group(HR=1.335,95%CI:0.812-2.193,p=0.254).The overall survival of the ALDH1+group-was lower than that of the ALDH1-group(HR=1.736,95%CI:0.385-0.864,P=0.008).Conclusion ALDH1+can be used as a marker of poor prognosis in early stage breast cancer,while CD44^+/CD24^-/low cannot be used as a marker of poor prognosis in early stage breast cancer.

关 键 词：乳腺癌 干细胞 CD44^+/CD24^-/low ALDH1+ 预后 

分 类 号：R737.9[医药卫生—肿瘤]